Launxp Biomedical Co

Launxp Biomedical Co FCF Growth

The Year-over-Year Free Cash Flow Growth of Launxp Biomedical Co (6876.TWO) as of Oct 18, 2026 is -23.25 %. In the previous year, Year-over-Year Free Cash Flow Growth was -38.73 % — a change of -39.96% (higher).

FCF Growth

-23.25 %

YoY

-39.96%

Last updated:

Year-over-Year Free Cash Flow Growth of Launxp Biomedical Co is 2024 -23.25 % . Year-over-Year Free Cash Flow Growth of Launxp Biomedical Co was 2023 -38.73 % . It decreases by -39.96% higher compared to the previous year.

The Launxp Biomedical Co FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2021
-23.92 TWD
Jan 1, 2022
-35.45 TWD
Jan 1, 2023
-38.73 TWD
Jan 1, 2024
-23.25 TWD
The Launxp Biomedical Co FCF Growth history
YEARFCF GrowthYoY
-23.25 %-39.96%
-38.73 %+9.26%
-35.45 %+48.20%
-23.92 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Launxp Biomedical Co Stock analysis

What does Launxp Biomedical Co do? Launxp Biomedical Co Ltd, headquartered in Taichung, Taiwan, is a biotechnology company focused on developing innovative cancer therapeutics. Listed on 18 January 2024, the company specializes in novel drug development, particularly targeting acute myeloid leukemia (AML) and other oncological conditions. Its pipeline includes LXPA1788, a multi-target kinase inhibitor; LXPA1988, a novel chemical structure drug targeting FLT3 mutations; and several other compounds with new indications and dosage forms for cancer treatment. Launxp Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Launxp Biomedical Co stock

Year-over-Year Free Cash Flow Growth of Launxp Biomedical Co is -23.25 % in 2024.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Launxp Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Launxp Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Launxp Biomedical Co

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Launxp Biomedical Co